You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

recurrent esophageal cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Esophageal Cancer Trial in Beijing (AN0025)

Not yet recruiting
  • Esophageal Cancer
  • Beijing, China
    Chinese PLA General Hospital
Jan 11, 2022

Esophageal Cancer Trial in Weihui, Suining, Beijing (Utidelone and anlotinib)

Recruiting
  • Esophageal Cancer
  • Utidelone and anlotinib
  • Weihui, Henan, China
  • +2 more
May 10, 2023

Esophageal Cancer Trial (Tislelizumab, Radiation, Paclitaxel)

Not yet recruiting
  • Esophageal Cancer
  • (no location specified)
Nov 18, 2022

Esophageal Cancer, Metastatic Cancer, Squamous Cell Carcinoma Trial in Taipei City (Cabozantinib 40 MG, Atezolizumab Injection)

Recruiting
  • Esophageal Cancer
  • +2 more
  • Cabozantinib 40 MG
  • Atezolizumab Injection
  • Taipei City, Taiwan
    National Taiwan University Hospital
Sep 15, 2022

Non-metastatic, Non-recurrent Lung and Esophageal Cancer

Recruiting
  • Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8
  • +55 more
  • Biospecimen Collection
  • +3 more
  • Scottsdale, Arizona
    Mayo Clinic in Arizona
Jan 5, 2023

Esophageal Squamous Cell Carcinomas Trial in Beijing (SI-B001, Irinotecan)

Recruiting
  • Esophageal Squamous Cell Carcinomas
  • Beijing, Beijing, China
    Beijing Cancer Hostital
Mar 14, 2022

Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced

Recruiting
  • Esophageal Neoplasms
  • an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor
  • Zhengzhou, Henan, China
    The First Affiliated Hospital of Zhengzhou University
Apr 21, 2022

Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma Trial in Kashiwa (Regorafenib,

Not yet recruiting
  • Gastric Adenocarcinoma
  • +2 more
  • Kashiwa, Chiba, Japan
    National Cancer Center Hospital East
May 23, 2022

Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma Trial in

Active, not recruiting
  • Metastatic Esophageal Carcinoma
  • +12 more
  • Corona, California
  • +31 more
Aug 9, 2022

Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC) Trial in Gainesville, Jacksonville (LITT +

Recruiting
  • Melanoma
  • +14 more
  • LITT + Pembrolizumab
  • Gainesville, Florida
  • +1 more
Aug 22, 2022

Ovarian Cancer, Ovarian Tumors, Ovarian Carcinoma Trial in United States (ELU001)

Recruiting
  • Ovarian Cancer
  • +68 more
  • Phoenix, Arizona
  • +8 more
Aug 18, 2022

Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach Trial in

Terminated
Has Results
  • Adenocarcinoma of the Esophagus
  • +13 more
  • oblimersen sodium
  • +2 more
  • Bronx, New York
    Montefiore Medical Center
Jan 29, 2021

Colorectal Cancer, Esophageal Cancer, Stomach Cancer Trial in Jinan (CEA CAR-T cells)

Recruiting
  • Colorectal Cancer
  • +5 more
  • CEA CAR-T cells
  • Jinan, Shandong, China
    The Second People's Hospital of Shandong Province
Jul 19, 2022

Gastric Cancer Stage IV Trial in Seoul (olaparib+pembrolizumab+paclitaxel)

Not yet recruiting
  • Gastric Cancer Stage IV
  • Seoul, Korea, Republic of
    Severance Hospital
Aug 29, 2021

Esophageal Stricture, Anastomotic Stenosis, Dilation of Esophagus Due to Disease Trial in Nijmegen (NKI followed by EBD)

Recruiting
  • Esophageal Stricture
  • +2 more
  • NKI followed by EBD
  • Nijmegen, Gelderland, Netherlands
    Radboudumc
Sep 16, 2021

Colorectal Cancer, Esophageal Cancer, Stomach Cancer Trial in Hangzhou (CEA CAR-T cells)

Recruiting
  • Colorectal Cancer
  • +5 more
  • CEA CAR-T cells
  • Hangzhou, Zhejiang, China
    First affiliated hospital, Zhejiang University
May 30, 2022

Esophageal Squamous Cell Carcinoma Trial in Beijing (Afatinib, Toripalimab)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Beijing, Beijing, China
    Peking University Cancer Hospital and Institute
Jul 11, 2021

Lung Cancer, Head Neck Cancer, Bladder Cancer Trial in London (S-488210, S-488211)

Completed
  • Lung Cancer
  • +4 more
  • S-488210
  • S-488211
  • London, United Kingdom
    University College London Clinical Research Facility
Jan 25, 2022

Relapsed or Advanced Gastric Adenocarcinoma, Gastro-esophageal Junction Cancer Trial in Seoul (autologous activated T

Recruiting
  • Relapsed or Advanced Gastric Adenocarcinoma
  • Gastro-esophageal Junction Cancer
  • autologous activated T lymphocyte
  • Seoul, Korea, Republic of
    Gangnam Severacen Hospital
Sep 15, 2021

Esophageal Squamous Cell Carcinoma Trial (Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin
  • (no location specified)
Aug 17, 2023

Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative Trial in Fullerton (Best Practice, Laboratory Biomarker

Active, not recruiting
  • Acute Myeloid Leukemia
  • +66 more
  • Best Practice
  • +3 more
  • Fullerton, California
    Virginia K Crosson Cancer Center
Jan 31, 2022

Recurrent Cancer, Prostate Cancer, Cervical Cancer Trial in Berlin (loco-regional hyperthermia)

Recruiting
  • Recurrent Cancer
  • +9 more
  • loco-regional hyperthermia
  • Berlin, Germany
    Klinik für Radioonkologie und Strahlentherapie
May 12, 2021

Esophageal Cancer Trial in Worldwide (Atezolizumab, Tiragolumab, Paclitaxel)

Active, not recruiting
  • Esophageal Cancer
  • Anyang City, China
  • +68 more
Jan 20, 2023

Esophageal Squamous Cell Carcinoma Trial in Worldwide (Tislelizumab, Ociperlimab, Placebo)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Hefei, Anhui, China
  • +85 more
Aug 19, 2022

Relapse in Esophageal Squamous Cell Cancers Who Achieve PCR to

Active, not recruiting
  • Esophageal Cancer
  • follow up
  • Guangzhou, Guangdong, China
    Jianhua Fu
Sep 24, 2023